L
LB Pharmaceuticals Inc (LBRX)
NGM – Real Time Price. Currency in USD
31.92
+0.92 (2.97%)
At close: Jun 26, 2026, 4:00 PM EDT
32.19
+0.27 (0.85%)
After-hours: Jun 26, 2026, 7:16 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
31.92
+0.92 (2.97%)
At close: Jun 26, 2026, 4:00 PM EDT
32.19
+0.27 (0.85%)
After-hours: Jun 26, 2026, 7:16 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $320.7M significantly exceed its total debt $3.5M, ensuring strong financial flexibility
Total current assets $389.1M exceed Total current liabilities $10.9M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$23.3M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 35.68 | 6.05 | 10 | |
| Quick ratio | 35.68 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -2K | -4K | -91K | -321K | -324K |
| Operating Income | -3M | -11M | -65M | -30M | -46M |
| Net Income | -14M | -6M | -63M | -25M | -39M |
| EBITDA | -3M | -11M | -65M | -30M | -46M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 42.86 | 5.5 |
| Next quarter | N/A | -55.27 | 1.0 |
| Current year | N/A | -12.55 | 1.0 |
| Next year | N/A | -24.49 | 1.0 |
| Weighted average score | 2.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -66.08 | -48.88 | -28.54 | 3.3 |
| Y/Y | 999 | -259.09 | N/A | -186.18 | 3.3 |
| 3y average | 999 | -263.08 | N/A | -217.93 | 3.3 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 2.7 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |